Inflammatory bowel disease: Difference between revisions
m Reverting possible vandalism by 138.217.211.41 to version by Crohnie. False positive? Report it. Thanks, ClueBot. (591645) (Bot) |
|||
| Line 56: | Line 56: | ||
==Recent findings== |
==Recent findings== |
||
This brand new in-depth market analysis examines the current and future prospects of the inflammatory bowel diseases (IBD) market. The world market for intestinal anti-inflammatories was worth over $2400 million in 2008, and had grown at 9% over the previous year.The value of other types of drugs used to treat IBD, including immunosuppressants and monoclonal antibodies, approached $12000m. [http://www.visiongain.com/Report.aspx?rid=366 More Details...] |
|||
A recent hypothesis posits that some IBD cases are caused by an overactive [[immune system]] attacking various tissues of the digestive tract because of the lack of traditional targets such as [[parasite]]s and worms. The number of people being diagnosed with IBD has increased as the number of infections by parasites, such as [[roundworm]], [[hookworm]] and [[human whipworm]]s, has fallen, and the condition is still rare in countries where parasitic infections are common. This is similar to the [[hygiene hypothesis]] applied to [[allergy|allergies]]. {{Fact|date=July 2007}} |
A recent hypothesis posits that some IBD cases are caused by an overactive [[immune system]] attacking various tissues of the digestive tract because of the lack of traditional targets such as [[parasite]]s and worms. The number of people being diagnosed with IBD has increased as the number of infections by parasites, such as [[roundworm]], [[hookworm]] and [[human whipworm]]s, has fallen, and the condition is still rare in countries where parasitic infections are common. This is similar to the [[hygiene hypothesis]] applied to [[allergy|allergies]]. {{Fact|date=July 2007}} |
||
Revision as of 09:37, 23 February 2009
| Inflammatory bowel disease | |
|---|---|
| Specialty | Gastroenterology  |
In medicine, inflammatory bowel disease (IBD) is a group of inflammatory conditions of the large intestine and small intestine. The major types of IBD are Crohn's disease and ulcerative colitis.[1][2][3].
Forms
The main forms of IBD are Crohn's disease and ulcerative colitis (UC).
Accounting for far fewer cases are other forms of IBD:
- Collagenous colitis
- Lymphocytic colitis
- Ischaemic colitis
- Diversion colitis
- Behçet's syndrome
- Infective colitis
- Indeterminate colitis
The main difference between Crohn's disease and UC is the location and nature of the inflammatory changes. Crohn's can affect any part of the gastrointestinal tract, from mouth to anus (skip lesions), although a majority of the cases start in the terminal ileum. Ulcerative colitis, in contrast, is restricted to the colon and the rectum. [1]
Microscopically, ulcerative colitis is restricted to the mucosa (epithelial lining of the gut), while Crohn's disease affects the whole bowel wall.
Finally, Crohn's disease and ulcerative colitis present with extra-intestinal manifestations (such as liver problems, arthritis, skin manifestations and eye problems) in different proportions.
Rarely, a definitive diagnosis of neither Crohn's disease nor ulcerative colitis can be made because of idiosyncrases in the presentation. In this case, a diagnosis of indeterminate colitis may be made. Although a recognised definition, not all centres refer to this.
Symptoms and diagnosis
Although very different diseases, both may present with any of the following symptoms: abdominal pain, vomiting, diarrhea, hematochezia (bright red blood in stools), weight loss and various associated complaints or diseases like arthritis, pyoderma gangrenosum, and primary sclerosing cholangitis. Diagnosis is generally by colonoscopy with biopsy of pathological lesions.
Treatment
Depending on the level of severity, IBD may require immunosuppression to control the symptom, such as prednisone, infliximab (Remicade), azathioprine (Imuran), methotrexate, or 6-mercaptopurine. More commonly, treatment of IBD requires a form of mesalamine. Often, steroids are used to control disease flares and were once acceptable as a maintenance drug. In use for several years in Crohn's disease patients and recently in patients with Ulcerative Colitis, biologicals have been used such as the intravenously administered Remicade. Severe cases may require surgery, such as bowel resection, strictureplasty or a temporary or permanent colostomy or ileostomy. Alternative medicine treatments for bowel disease exist in various forms, however such methods concentrate on controlling underlying pathology in order to avoid prolonged steroidal exposure or surgical excisement[2].
Usually the treatment is started by administering drugs with high anti-inflammatory affects, such as prednisone. Once the inflammation is successfully controlled, the patient is usually switched to a lighter drug to keep the disease in remission, such as Asacol, a mesalamine. If unsuccessful, a combination of the aforementioned immunosuppression drugs with a mesalamine (which may also have an anti-inflammatory effect) may or may not be administered, depending on the patient.
Prognosis
While IBD can limit quality of life because of pain, vomiting, diarrhea, and other socially unacceptable symptoms, it is rarely fatal on its own. Fatalities due to complications such as toxic megacolon, bowel perforation and surgical complications are also rare.
While patients of IBD do have an increased risk of colorectal cancer this is usually caught much earlier than the general population in routine surveillance of the colon by colonoscopy, and therefore patients are much more likely to survive.
New evidence suggests that patients with IBD may have an elevated risk of endothelial dysfunction and coronary artery disease[4].
The goal of treatment is toward achieving remission, after which the patient is usually switched to a lighter drug with fewer potential side effects. Every so often an acute resurgence of the original symptoms may appear: this is known as a "flare-up". Depending on the circumstances, it may go away on its own or require medication. The time between flare-ups may be anywhere from weeks to years, and varies wildly between patients - a few have never experienced a flare-up.
Recent findings
This brand new in-depth market analysis examines the current and future prospects of the inflammatory bowel diseases (IBD) market. The world market for intestinal anti-inflammatories was worth over $2400 million in 2008, and had grown at 9% over the previous year.The value of other types of drugs used to treat IBD, including immunosuppressants and monoclonal antibodies, approached $12000m. More Details...
A recent hypothesis posits that some IBD cases are caused by an overactive immune system attacking various tissues of the digestive tract because of the lack of traditional targets such as parasites and worms. The number of people being diagnosed with IBD has increased as the number of infections by parasites, such as roundworm, hookworm and human whipworms, has fallen, and the condition is still rare in countries where parasitic infections are common. This is similar to the hygiene hypothesis applied to allergies. [citation needed]
Initial reports[5] suggest that "helminthic therapy" may not only prevent but even cure (or control) IBD: a drink with roughly 2,500 ova of the Trichuris suis helminth taken twice monthly decreased symptoms markedly in many patients. It is even speculated that an effective "immunization" procedure could be developed—by ingesting the cocktail at an early age.
Prebiotics and probiotics are showing increasing promise as treatments for IBD[6] and in some studies have proven to be as effective as prescription drugs.[7]
More recently, research[8] has shown that IL-23 is overexpressed in tissues taken from Mouse models of IBD. The group showed that knocking out IL-23 (heterodimer of IL-12p40 and IL-23p19) sharply reduced inflammation of the bowel, both in terms of cells and proinflammatory cytokine production. Also, they found that a novel group of CD4+ T lymphocytes, Th17 T cells, are highly unregulated in bowels of diseased mice. Taken together, the group shows that IL-23 but not IL-12 (IL-12p40 and IL-12p35; share a subunit) drives innate and T cell mediated intestinal inflammation.
In 2005 New Scientist published a joint study by Bristol University and Bath University on the apparent healing power of cannabis on IBD. Reports that cannabis eased IBD symptoms indicated the possible existence of cannabinoid receptors in the intestinal lining, which respond to molecules in the plant-derived chemicals. CB1 cannabinoid receptors – which are known to be present in the brain – exist in the endothelial cells which line the gut, it is thought that they are involved in repairing the lining of the gut when damaged. The team deliberately damaged the cells to cause inflammation of the gut lining and then added synthetically produced cannabinoids; the result was that gut started to heal: the broken cells were repaired and brought back closer together to mend the tears. It is believed that in a healthy gut, natural endogenous cannabinoids are released from endothelial cells when they are injured, which then bind to the CB1 receptors. The process appears to set off a wound-healing reaction, and when people use cannabis, the cannabinoids bind to these receptors in the same way. Previous studies have shown that CB1 receptors located on the nerve cells in the gut respond to cannabinoids by slowing gut motility, therefore reducing the painful muscle contractions associated with diarrhoea. The team also discovered another cannabinoid receptor, CB2, in the guts of IBD sufferers, which was not present in healthy guts. These receptors, which also respond to chemicals in cannabis, appear to be associated with apoptosis – programmed cell death – and may have a role in suppressing the overactive immune system and reducing inflammation by moping up excess cells.[9]
Genetics play a crucial role in Crohn's disease but environmental factors are also involved; smoking appears to increase the risk.
References
- ^ Baumgart DC, Carding SR (2007). "Inflammatory bowel disease: cause and immunobiology". The Lancet. 369 (9573): 1627–40. doi:10.1016/S0140-6736(07)60750-8. PMID 17499605.
- ^ Baumgart DC, Sandborn WJ (2007). "Inflammatory bowel disease: clinical aspects and established and evolving therapies". The Lancet. 369 (9573): 1641–57. doi:10.1016/S0140-6736(07)60751-X. PMID 17499606.
- ^ Xavier RJ, Podolsky DK (2007). "Unravelling the pathogenesis of inflammatory bowel disease". Nature. 448 (7152): 427–34. doi:10.1038/nature06005. PMID 17653185.
- ^ Idan Roifman, YC Sun, Jason P. Fedwick, Remo Panaccione, Andre G Buret, Alaa Rostom, Todd J Anderson, Paul L. Beck., Evidence of Endothelial Dysfunction in Patients with Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. Oct 2008 (epub ahead of print)
- ^ Summers RW, Elliott DE, Qadir K, Urban JF, Thompson R, Weinstock JV (2003). "Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease". Am. J. Gastroenterol. 98 (9): 2034–41. doi:10.1111/j.1572-0241.2003.07660.x. PMID 14499784.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Furrie E, Macfarlane S, Kennedy A; et al. (2005). "Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial". Gut. 54 (2): 242–9. doi:10.1136/gut.2004.044834. PMC 1774839. PMID 15647189.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link) - ^ Kruis W, Fric P, Pokrotnieks J; et al. (2004). "Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine". Gut. 53 (11): 1617–23. doi:10.1136/gut.2003.037747. PMC 1774300. PMID 15479682.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link) - ^ Hue S, Ahern P, Buonocore S; et al. (2006). "Interleukin-23 drives innate and T cell-mediated intestinal inflammation". J. Exp. Med. 203 (11): 2473–83. doi:10.1084/jem.20061099. PMC 2118132. PMID 17030949.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link) - ^ Wright K, Rooney N, Feeney M; et al. (2005). "Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing". Gastroenterology. 129 (2): 437–53. doi:10.1016/j.gastro.2005.05.026. PMID 16083701.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)